Elisa M Ledet1, Emmanuel S Antonarakis2, William B Isaacs3, Tamara L Lotan3, Colin Pritchard4, A Oliver Sartor1. 1. Tulane Cancer Center, New Orleans, Louisiana. 2. Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland. 3. James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland. 4. University of Washington, Seattle, Washington.
Abstract
BACKGROUND: Biallelic loss-of-function BLM mutations result in Bloom syndrome: a genetic disorder characterized by growth deficiencies, photosensitivity, and multiple cancer susceptibilities. There are conflicting reports about whether or not heterozygous BLM carriers are at a higher risk of various cancers. Without BLM protein functionality, there is evidence of increased sister chromatid exchange and chromosomal instability. METHODS: Metastatic prostate cancer patients (N = 796) underwent germline genetic testing as part of routine care at three academic centers. Patients with heterozygous BLM mutations were identified. Tumor tissue was analyzed for somatic alterations in those patients who had a germline pathogenic mutation. Control data using a population sample were extracted from the Genome Aggregation Database. RESULTS: Heterozygous BLM germline mutations in 5 of 796 patients (prevalence, 0.63%). All mutations were loss-of-function truncating alterations. None of the mutations were BLMAsh . The control population (gnomAD) frequency of pathogenic or likely pathogenic BLM mutations was 0.18% (212 of 116 653). The relative risk (RR) of BLM mutations in metastatic prostate cancer patients was 3.4 (95% CI, 1.42-8.33; P < .0062) compared to gnomAD controls. Tumor DNA sequencing in the BLM carriers showed no evidence of somatic BLM mutations. Interestingly, 3 of 5 BLM germline carriers had bi-allelic BRCA2 inactivation evident on tumor sequencing. One patient had both germline and somatic mutations in BRCA2. Excluding the patient with the germline BRCA2 mutation (BLM prevalence, 4 of 796: 0.50%) still yielded a statistically significant finding vs the gnomAD controls (RR, 2.8; 95% CI, 1.02-7.39; P < .04). CONCLUSION: Truncating BLM germline mutations occur at a higher frequency in patients with advanced prostate cancer as compared to control populations. Though no biallelic loss of BLM was no noted in cancers, a surprising number of the BLM germline heterozygotes had pathogenic BRCA2 mutations in their tumor.
BACKGROUND: Biallelic loss-of-function BLM mutations result in Bloom syndrome: a genetic disorder characterized by growth deficiencies, photosensitivity, and multiple cancer susceptibilities. There are conflicting reports about whether or not heterozygous BLM carriers are at a higher risk of various cancers. Without BLM protein functionality, there is evidence of increased sister chromatid exchange and chromosomal instability. METHODS:Metastatic prostate cancerpatients (N = 796) underwent germline genetic testing as part of routine care at three academic centers. Patients with heterozygous BLM mutations were identified. Tumor tissue was analyzed for somatic alterations in those patients who had a germline pathogenic mutation. Control data using a population sample were extracted from the Genome Aggregation Database. RESULTS: Heterozygous BLM germline mutations in 5 of 796 patients (prevalence, 0.63%). All mutations were loss-of-function truncating alterations. None of the mutations were BLMAsh . The control population (gnomAD) frequency of pathogenic or likely pathogenic BLM mutations was 0.18% (212 of 116 653). The relative risk (RR) of BLM mutations in metastatic prostate cancerpatients was 3.4 (95% CI, 1.42-8.33; P < .0062) compared to gnomAD controls. Tumor DNA sequencing in the BLM carriers showed no evidence of somatic BLM mutations. Interestingly, 3 of 5 BLM germline carriers had bi-allelic BRCA2 inactivation evident on tumor sequencing. One patient had both germline and somatic mutations in BRCA2. Excluding the patient with the germline BRCA2 mutation (BLM prevalence, 4 of 796: 0.50%) still yielded a statistically significant finding vs the gnomAD controls (RR, 2.8; 95% CI, 1.02-7.39; P < .04). CONCLUSION: Truncating BLM germline mutations occur at a higher frequency in patients with advanced prostate cancer as compared to control populations. Though no biallelic loss of BLM was no noted in cancers, a surprising number of the BLM germline heterozygotes had pathogenic BRCA2 mutations in their tumor.
Authors: Stephen B Gruber; Nathan A Ellis; Karen K Scott; Ronit Almog; Prema Kolachana; Joseph D Bonner; Tomas Kirchhoff; Lynn P Tomsho; Khedoudja Nafa; Heather Pierce; Marcelo Low; Jaya Satagopan; Hedy Rennert; Helen Huang; Joel K Greenson; Joanna Groden; Beth Rapaport; Jinru Shia; Stephen Johnson; Peter K Gregersen; Curtis C Harris; Jeff Boyd; Gad Rennert; Kenneth Offit Journal: Science Date: 2002-09-20 Impact factor: 47.728
Authors: Anna M Johnson; Kimberly A Zuhlke; Chris Plotts; Shannon K McDonnell; Sumit Middha; Shaun M Riska; Daniel J Schaid; Stephen N Thibodeau; Julie A Douglas; Kathleen A Cooney Journal: Prostate Date: 2014-08-11 Impact factor: 4.104
Authors: Andrzej Antczak; Wojciech Kluźniak; Dominika Wokołorczyk; Aniruddh Kashyap; Anna Jakubowska; Jacek Gronwald; Tomasz Huzarski; Tomasz Byrski; Tadeusz Dębniak; Bartłomiej Masojć; Bohdan Górski; Tomasz Gromowski; Agnieszka Nagorna; Adam Gołąb; Andrzej Sikorski; Marcin Słojewski; Bartłomiej Gliniewicz; Tomasz Borkowski; Andrzej Borkowski; Jacek Przybyła; Marek Sosnowski; Bartosz Małkiewicz; Romuald Zdrojowy; Paulina Sikorska-Radek; Józef Matych; Jacek Wilkosz; Waldemar Różański; Jacek Kiś; Krzysztof Bar; Paweł Domagała; Małgorzata Stawicka; Piotr Milecki; Mohammad R Akbari; Steven A Narod; Jan Lubiński; Cezary Cybulski; Piotr Bryniarski; Andrzej Paradysz; Konrad Jersak; Jerzy Niemirowicz; Piotr Słupski; Piotr Jarzemski; Michał Skrzypczyk; Jakub Dobruch; Wenancjusz Domagała; Maria Chosia; Thierry van de Wetering; Pablo Serrano-Fernández; Michał Puszyński; Michał Soczawa; Jerzy Switała; Sławomir Archimowicz; Mirosław Kordowski; Marcin Zyczkowski; Andrzej Borówka; Joanna Bagińska; Kazimierz Krajka; Marek Szwiec; Olga Haus; Hanna Janiszewska; Agnieszka Stembalska; Maria Małgorzata Sąsiadek Journal: Gene Date: 2013-10-02 Impact factor: 3.688
Authors: Colin C Pritchard; Joaquin Mateo; Michael F Walsh; Navonil De Sarkar; Wassim Abida; Himisha Beltran; Andrea Garofalo; Roman Gulati; Suzanne Carreira; Rosalind Eeles; Olivier Elemento; Mark A Rubin; Dan Robinson; Robert Lonigro; Maha Hussain; Arul Chinnaiyan; Jake Vinson; Julie Filipenko; Levi Garraway; Mary-Ellen Taplin; Saud AlDubayan; G Celine Han; Mallory Beightol; Colm Morrissey; Belinda Nghiem; Heather H Cheng; Bruce Montgomery; Tom Walsh; Silvia Casadei; Michael Berger; Liying Zhang; Ahmet Zehir; Joseph Vijai; Howard I Scher; Charles Sawyers; Nikolaus Schultz; Philip W Kantoff; David Solit; Mark Robson; Eliezer M Van Allen; Kenneth Offit; Johann de Bono; Peter S Nelson Journal: N Engl J Med Date: 2016-07-06 Impact factor: 91.245